Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Biogen Inc

BIIB
Current price
232.85 USD -1.26 USD (-0.54%)
Last closed 234.64 USD
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 33 998 866 432 USD
Yield for 12 month -20.46 %
Week
Month
Year
BIIB
21.11.2021 - 28.11.2021

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Address: 225 Binney Street, Cambridge, MA, United States, 02142

Analytics

WallStreet Target Price

323.48 USD

P/E ratio

23.3009

Dividend Yield

3.71 %

Current Year

+10 173 400 000 USD

Last Year

+10 981 700 000 USD

Current Quarter

+2 530 300 000 USD

Last Quarter

+2 456 000 000 USD

Current Year

+7 895 100 000 USD

Last Year

+8 872 000 000 USD

Current Quarter

+1 870 700 000 USD

Last Quarter

+1 863 300 000 USD

Key Figures BIIB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 2 536 600 064 USD
Operating Margin TTM 10.69 %
PE Ratio 23.3009
Return On Assets TTM 4.86 %
PEG Ratio 6.2424
Return On Equity TTM 10.73 %
Wall Street Target Price 323.48 USD
Revenue TTM 9 993 299 968 USD
Book Value 99.96 USD
Revenue Per Share TTM 69.17 USD
Dividend Share
Quarterly Revenue Growth YOY 0.9 %
Dividend Yield 3.71 %
Gross Profit TTM 7 895 100 000 USD
Earnings Share 10.07 USD
Diluted Eps TTM 10.07 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -43.8 %
Profit Margin 14.63 %

Dividend Analytics BIIB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BIIB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 3.71 %
Last Split Factor 3:1
Payout Ratio
Last Split Date 18.01.2001
Dividend Date

Stock Valuation BIIB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 23.3009
Forward PE 14.3062
Enterprise Value Revenue 3.9457
Price Sales TTM 3.4022
Enterprise Value EBITDA 17.0422
Price Book MRQ 2.3477

Financials BIIB

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BIIB

For 52 weeks

220.86 USD 319.76 USD
50 Day MA 245.66 USD
Shares Short Prior Month 2 692 752
200 Day MA 271.84 USD
Short Ratio 2.24
Shares Short 2 631 344
Short Percent 2.05 %